Results 11 to 20 of about 841 (115)

Nano-PROTACs: state of the art and perspectives

Nanoscale
PROteolysis TArgeting Chimeras (PROTACs), as a recently identified technique in the field of new drug development, provide new concepts for disease treatment and are expected to revolutionize drug discovery. With high specificity and flexibility, PROTACs
Jie Zhong, Yuji Wang, Yu-xiong Su
exaly   +4 more sources

Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

Advanced Science, 2023
PROteolysis TArgeting Chimeras (PROTACs) are an emerging class of promising therapeutic modalities that selectively degrade intracellular proteins of interest by hijacking the ubiquitin‐proteasome system.
Hai‐Jun Liu, Wei Chen, Gongwei Wu, Jun Zhou, Chuang Liu, Zhongmin Tang, Xiangang Huang, Jingjing Gao, Yufen Xiao, Na Kong, Nitin Joshi, Yihai Cao, Reza Abdi, Wei Tao   +13 more
doaj   +2 more sources

pH-Activatable engineered nanoparticle-based selective hexokinase 2 degrader provokes GSDME-dependent pyroptosis for cancer therapy [PDF]

Acta Pharmaceutica Sinica B
Proteolysis targeting chimeras (PROTACs) technology has been developed as an exquisite promising approach for targeted protein degradation by hijacking the cellular ubiquitin-proteasome system (UPS).
Linlin Gong, Shasha Li, Jiahui Sun, Kunhong Liu, Simeng Wang, Meiju Ji, Peng Hou, Li Yan, Dan Yang, Dechun Liu   +9 more
doaj   +2 more sources

Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy

Advanced Materials, 2022
Checkpoint immunotherapy holds great potential to treat malignancies via blocking the immunosuppressive signaling pathways, which however suffers from inefficiency and off-target adverse effects.
He, Shasha, Huang, Jingsheng, Pu, Kanyi, Xu, Cheng, Xu, Mengke, Zhang, Chi   +5 more
core   +4 more sources

Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy

Signal Transduction and Targeted Therapy
Photodynamic therapy (PDT) induces tumor cell pyroptosis, a form of programmed cell death that triggers antitumor immunity. However, high glucose metabolism and hypoxic conditions in the tumor microenvironment (TME) limit PDT efficiency and impair ...
Byeongmin Park, Jiwoong Choi, Jae-Hyeon Lee, Yelee Kim, Woohyeong Lee, Ansoo Lee, In-Cheol Sun, Hong Yeol Yoon, Yongju Kim, Sun Hwa Kim, Yoosoo Yang, Kwangmeyung Kim, Jooho Park, Man Kyu Shim   +13 more
doaj   +4 more sources

Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy

Nano Biomedicine and Engineering
Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic strategy for targeted protein degradation. They offer several advantages over traditional small-molecule inhibitors, including catalytic efficiency, high specificity, and ...
Zhimin Weng, Jiaojiao Yu, Yuanrong Liao, Yuanyuan Zhang, Changmai Chen, Wei Chen   +5 more
doaj   +2 more sources

Multifunctional Engineered Metal–Organic Frameworks as Targeted Protein Degraders for Augmenting Cancer Therapy via Hexokinase 2 Degradation and Provoking Cuproptosis [PDF]

Research
Cuproptosis, a newly identified form of copper-dependent programmed cell death, has emerged as a potential therapeutic strategy for cancer treatment.
Shasha Li, Runjie Liu, Qixuan Zhang, Jiahui Sun, Hao Hao, Chenhao Yao, Li Yan, Dan Yang, Dechun Liu   +8 more
doaj   +2 more sources

PROTAC-Based Antivirals for Respiratory Viruses: A Novel Approach for Targeted Therapy and Vaccine Development. [PDF]

Microorganisms
The global burden of respiratory viral infections is notable, which is attributed to their higher transmissibility compared to other viral diseases. Respiratory viruses are seen to have evolved resistance to available treatment options. Although vaccines
Anugu A, Singh P, Kashyap D, Joseph J, Naik S, Sarkar S, Zaman K, Dhaliwal M, Nagar S, Gupta T, Honnavar P.   +10 more
europepmc   +3 more sources

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery

Materials Today Advances
Proteolysis-targeting chimeras (PROTACs) have revolutionized drug discovery by enabling targeted protein degradation via the ubiquitin-proteasome system (UPS), overcoming limitations of traditional occupancy-based inhibitors. This innovative approach has
Jinghua Yang, Yujing Zhang, Miao Zhang, Dongming Xing, Chao Wang   +4 more
doaj   +2 more sources

Advancing cancer immunotherapy: Small-Molecule, biomacromolecular, and nanoscale PROTACs targeting PD-L1 for degradation

Materials Today Advances
Programmed death-ligand 1 (PD-L1) is a key immune checkpoint protein that enables tumor immune evasion by engaging PD-1 on T cells, thereby inhibiting their cytotoxic function.
Yang Meng, Yujing Zhang, Wanpeng Yu, Dongming Xing, Chao Wang   +4 more
doaj   +3 more sources